Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Telix Pharmaceuticals Ltd TLX

Alternate Symbol(s):  TLPPF

Healthcare Biotechnology
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC... see more

Current News (NDAQ:TLX)

Telix Full Year Results 2025 Investor Webcast Notification

GlobeNewswire 4 days ago

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

GlobeNewswire January 20, 2026

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

GlobeNewswire January 16, 2026

Class Action Lawsuit Reminder from Pomerantz LLP for Investors of Telix Pharmaceuticals Limited - TLX

ACCESS Newswire January 9, 2026

Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX

GlobeNewswire January 9, 2026

TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights

GlobeNewswire January 9, 2026

FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026

Business Wire January 9, 2026

Pomerantz LLP Notifies Investors of Class Action Filing Against Telix Pharmaceuticals Limited - TLX

ACCESS Newswire January 9, 2026

TLX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Telix Pharmaceuticals Limited Investors to Participate in the Class Action Lawsuit

ACCESS Newswire January 9, 2026
View More News ››

Opinion & Analysis (NDAQ:TLX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TLX)

Be the first to post on this bullboard.

McFarlane Lake Mining Ltd.

McFarlane Lake Mining Ltd.

McFarlane Lake Mining Limited engages in the acquisition and exploration of mineral resource properties in Canada. It ...
View More »

Podcasts